Cuproptosis in ccRCC: key player in therapeutic and prognostic targets
BackgroundClassical biomarkers have been used to classify clear cell renal cell carcinoma (ccRCC) patients in a variety of ways, and emerging evidences have indicated that cuproptosis is closely related to mitochondrial metabolism, thereby accelerating the development and progression of ccRCC. Never...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-10-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1271864/full |
| _version_ | 1797646931240943616 |
|---|---|
| author | Yang Lv Qiang Li Lu Yin Shaohua He Chao Qin Zhongwen Lu Hongqi Chen |
| author_facet | Yang Lv Qiang Li Lu Yin Shaohua He Chao Qin Zhongwen Lu Hongqi Chen |
| author_sort | Yang Lv |
| collection | DOAJ |
| description | BackgroundClassical biomarkers have been used to classify clear cell renal cell carcinoma (ccRCC) patients in a variety of ways, and emerging evidences have indicated that cuproptosis is closely related to mitochondrial metabolism, thereby accelerating the development and progression of ccRCC. Nevertheless, the specific relationship between cuproptosis and the prognosis and treatment of ccRCC remains unclear.MethodsWe comprehensively integrated several ccRCC patient datasets into a large cohort. Following that, we systematically analyzed multi-omics data to demonstrate the differences between two cuproptosis clusters.ResultsWe identified two cuproptosis clusters in ccRCC patients. Among the two clusters, cluster 1 patients showed favorable prognosis. We then confirmed the significant differences between the two clusters, including more typical cancer hallmarks were enriched in cluster 2 patients; cluster 2 patients were more susceptible to develop mutations and had a lower level of gistic score and mRNAsi. Importantly, both Tumor Immune Dysfunction and Exclusion analysis and subclass mapping algorithm showed that cuproptosis 1 patients were more susceptible to be responded to immunotherapy. In addition, a prognostic signature was successfully developed and also showed prominent predictive power in response to immunotherapy.ConclusionAs a result of our findings, we were able to classify ccRCC patients according to cuproptosis in a novel way. By constructing the cuproptosis clusters and developing the signature, patients with ccRCC could have a more accurate prognosis prediction and better immunotherapy options. |
| first_indexed | 2024-03-11T15:10:00Z |
| format | Article |
| id | doaj.art-98d088af14de4aa0b45d5090025d6498 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-11T15:10:00Z |
| publishDate | 2023-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-98d088af14de4aa0b45d5090025d64982023-10-29T17:12:25ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-10-011310.3389/fonc.2023.12718641271864Cuproptosis in ccRCC: key player in therapeutic and prognostic targetsYang Lv0Qiang Li1Lu Yin2Shaohua He3Chao Qin4Zhongwen Lu5Hongqi Chen6Department of Urology, The Affiliated Jiangsu Shengze Hospital of Nanjing Medical University, Suzhou, ChinaDepartment of Urology, The Affiliated Jiangsu Shengze Hospital of Nanjing Medical University, Suzhou, ChinaDepartment of Traditional Chinese Medicine, Hong Kong Baptist University, Hong Kong, Hong Kong SAR, ChinaDepartment of Urology, The Affiliated Jiangsu Shengze Hospital of Nanjing Medical University, Suzhou, ChinaDepartment of Urology, The Affiliated Jiangsu Shengze Hospital of Nanjing Medical University, Suzhou, ChinaDepartment of Urology, The Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Urology, The Affiliated Jiangsu Shengze Hospital of Nanjing Medical University, Suzhou, ChinaBackgroundClassical biomarkers have been used to classify clear cell renal cell carcinoma (ccRCC) patients in a variety of ways, and emerging evidences have indicated that cuproptosis is closely related to mitochondrial metabolism, thereby accelerating the development and progression of ccRCC. Nevertheless, the specific relationship between cuproptosis and the prognosis and treatment of ccRCC remains unclear.MethodsWe comprehensively integrated several ccRCC patient datasets into a large cohort. Following that, we systematically analyzed multi-omics data to demonstrate the differences between two cuproptosis clusters.ResultsWe identified two cuproptosis clusters in ccRCC patients. Among the two clusters, cluster 1 patients showed favorable prognosis. We then confirmed the significant differences between the two clusters, including more typical cancer hallmarks were enriched in cluster 2 patients; cluster 2 patients were more susceptible to develop mutations and had a lower level of gistic score and mRNAsi. Importantly, both Tumor Immune Dysfunction and Exclusion analysis and subclass mapping algorithm showed that cuproptosis 1 patients were more susceptible to be responded to immunotherapy. In addition, a prognostic signature was successfully developed and also showed prominent predictive power in response to immunotherapy.ConclusionAs a result of our findings, we were able to classify ccRCC patients according to cuproptosis in a novel way. By constructing the cuproptosis clusters and developing the signature, patients with ccRCC could have a more accurate prognosis prediction and better immunotherapy options.https://www.frontiersin.org/articles/10.3389/fonc.2023.1271864/fullclear cell renal cell carcinomacuproptosistumor immune microenvironmentimmunotherapyprognosis |
| spellingShingle | Yang Lv Qiang Li Lu Yin Shaohua He Chao Qin Zhongwen Lu Hongqi Chen Cuproptosis in ccRCC: key player in therapeutic and prognostic targets Frontiers in Oncology clear cell renal cell carcinoma cuproptosis tumor immune microenvironment immunotherapy prognosis |
| title | Cuproptosis in ccRCC: key player in therapeutic and prognostic targets |
| title_full | Cuproptosis in ccRCC: key player in therapeutic and prognostic targets |
| title_fullStr | Cuproptosis in ccRCC: key player in therapeutic and prognostic targets |
| title_full_unstemmed | Cuproptosis in ccRCC: key player in therapeutic and prognostic targets |
| title_short | Cuproptosis in ccRCC: key player in therapeutic and prognostic targets |
| title_sort | cuproptosis in ccrcc key player in therapeutic and prognostic targets |
| topic | clear cell renal cell carcinoma cuproptosis tumor immune microenvironment immunotherapy prognosis |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1271864/full |
| work_keys_str_mv | AT yanglv cuproptosisinccrcckeyplayerintherapeuticandprognostictargets AT qiangli cuproptosisinccrcckeyplayerintherapeuticandprognostictargets AT luyin cuproptosisinccrcckeyplayerintherapeuticandprognostictargets AT shaohuahe cuproptosisinccrcckeyplayerintherapeuticandprognostictargets AT chaoqin cuproptosisinccrcckeyplayerintherapeuticandprognostictargets AT zhongwenlu cuproptosisinccrcckeyplayerintherapeuticandprognostictargets AT hongqichen cuproptosisinccrcckeyplayerintherapeuticandprognostictargets |